What is the impact of SGLT-2i trials in HFpEF? from Let's Talk! - Prof. Andrew Coats

Click on the timestamp to jump to the topic you are interested in.

• 00:56 The story of SGLT2i in heart failure 01:40 Patients with HFpEF suffer from poor outcomes 02:19 Empagliflozin is the first HF drug to significantly reduce the risk OF CD death or HHF across the full LVEF spectrum 03:56 EMPULSE complements the EMPEROR trials across the LVEF spectrum